ArticleCancer discovery2018
A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.
- Clinical Evidence of Chemotherapy or Endocrine Therapy Maintenance in Patients with Metastatic Breast Cancer: Meta-Analysis of Randomized Clinical Trials and Propensity Score Matching of Multicenter Cohort Study.Cancer research and treatment · 2022Pooled it
- Prognostic Impact of Thoracic Duct Resection in Patients Who Underwent Transthoracic Esophagectomy Following Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma: Exploratory Analysis of JCOG1109.Annals of surgical oncology · 2025Trial
- Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.Breast cancer research : BCR · 2021Trial
- Tumor evolution: signaling pathways, molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Early detection of aberrant cell fate and repair using circulating progenitor cells in patients with heterotopic ossification.Nature communications · 2026Article
- Isoliquiritigenin Impedes Breast Cancer Progression through PITX1-PFKP-Mediated Glycolysis Reprogramming.Oncology research · 2026Article
- Circulating tumor cells: Blood-based detection, molecular biology, and clinical applications.Cancer cell · 2025Review
- Deciphering Breast Tumor Heterogeneity Through Patient-Derived Organoids and Circulating Tumor Cells.Journal of personalized medicine · 2025Review
- Enter sandman: how to tackle dormant breast cancer cells.Medical oncology (Northwood, London, England) · 2025Review
- Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product.Nature communications · 2025Article
- Safety and Efficacy of Conversion Therapy After Systemic Chemotherapy in Advanced Esophageal Cancer with Distant Metastases: A Multicenter Retrospective Observational Study.Annals of surgical oncology · 2025Observational
- Article
- Searching for the "Holy Grail" of breast cancer recurrence risk: a narrative review of the hunt for a better biomarker and the promise of circulating tumor DNA (ctDNA).Breast cancer research and treatment · 2024Review
- Clinical significance of postoperative folate receptor-positive circulating tumor cells (FR + CTCs) for long-term prognosis in patients with invasive adenocarcinoma (IAC) of the lung.Thoracic cancer · 2024Article
- Article
- The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring.Cell reports. Medicine · 2023Review
- Deciphering the Biology of Circulating Tumor Cells through Single-Cell RNA Sequencing: Implications for Precision Medicine in Cancer.International journal of molecular sciences · 2023Review
- Novel method for highly multiplexed gene expression profiling of circulating tumor cells (CTCs) captured from the blood of women with metastatic breast cancer.Journal of translational medicine · 2023Article
- Detection and Molecular Characterization of Circulating Tumour Cells: Challenges for the Clinical Setting.Cancers · 2023Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 1 country.
Tanya T Kwan *Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.
Aditya Bardia *Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.
Laura M SpringMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.
Anita Giobbie-HurderDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Mark KalinichMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.
Taronish DubashMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.
Tilak SundaresanMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.
Xin HongMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.
Joseph A LiCausiMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.
Uyen HoMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.
Erin J SilvaMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.
Ben S WittnerMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.
Lecia V SequistMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.ORCID 0000-0002-8965-6991
Ravi KapurCenter for Bioengineering in Medicine, Massachusetts General Hospital and Harvard Medical School, and Shriners Hospital for Children, Boston, Massachusetts.
David T MiyamotoMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.
Mehmet TonerCenter for Bioengineering in Medicine, Massachusetts General Hospital and Harvard Medical School, and Shriners Hospital for Children, Boston, Massachusetts.
Daniel A HaberMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts. dhaber@mgh.harvard.edu maheswaran@helix.mgh.harvard.edu.
Shyamala MaheswaranMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts. dhaber@mgh.harvard.edu maheswaran@helix.mgh.harvard.edu.
Massachusetts General Hospital · USShriners Hospitals for Children - Erie · USDana-Farber Cancer Institute · USHoward Hughes Medical Institute · US
Funding
Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2MMedical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0MPoint-of care Microfluidics for Early Detection of CancerU01EB012493 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI HABER, DANIEL A., TONER, MEHMET · 2010 to 2018
$19.6MDana Farber/Harvard Cancer Consortium Career Development Program in Clinical OncologyK12CA087723 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Tsai Ting · 2002 to 2026
$17.9MHarvard Clinical and Translational Science CenterKL2TR001100 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$8.5MModeling Metastasis and Acquired Drug Resistance Using Circulating Tumor CellsR01CA129933 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel A. Haber · 2008 to 2026
$7.5MMetastasis and biophysics of clusters of circulating tumor cells in the microcirculationU01CA214297 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HABER, DANIEL A., MAHESWARAN, SHYAMALA · 2018 to 2022
$2.9MMechanically mediated genomic changes during the metastatic cascadeF30CA224588 · NCI · HARVARD MEDICAL SCHOOL · PI KALINICH, MARK · 2018 to 2019
$86kHoward Hughes Medical InstituteNCATS NIH HHS KL2 TR001100NCATS NIH HHS UL1 TR001102NCI NIH HHS F30 CA224588NCI NIH HHS K12 CA087723NCI NIH HHS R01 CA129933NCI NIH HHS U01 CA214297NIBIB NIH HHS U01 EB012493NIGMS NIH HHS T32 GM007753
Abstract
The multiplicity of new therapies for breast cancer presents a challenge for treatment selection. We describe a 17-gene digital signature of breast circulating tumor cell (CTC)-derived transcripts enriched from blood, enabling high-sensitivity early monitoring of response. In a prospective cohort of localized breast cancer, an elevated CTC score after three cycles of neoadjuvant therapy is associated with residual disease at surgery (
Indexed as
Breast NeoplasmsFemaleHumansNeoplasm MetastasisNeoplastic Cells, CirculatingRNARNA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.